Bionano Genomics (BNGO) Cash & Current Investments (2017 - 2026)

Bionano Genomics has reported Cash & Current Investments for 10 years, with the latest figure at $13.7 million in Q1 2026.

• Quarterly Cash & Current Investments fell 24.9% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (down 24.9% YoY) and the FY2025 annual result came in at $13.3 million, down 34.12% from the prior year.
• Cash & Current Investments improved to $13.7 million in Q1 2026 per BNGO's latest filing, from $13.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $216.5 million in Q1 2022 and troughed at $5.1 million in Q4 2022.
• A 5-year average of $62.2 million and a median of $21.6 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments slumped 97.97% in 2022, then jumped 1211.55% in 2023.
• Over 5 years, Cash & Current Investments stood at $5.1 million in 2022, then surged by 1211.55% to $66.8 million in 2023, then slumped by 69.79% to $20.2 million in 2024, then sank by 34.12% to $13.3 million in 2025, then climbed by 3.02% to $13.7 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $13.7 million, $13.3 million, and $21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.